Studies on new substituted pyridazinones: synthesis and biological evaluation by Asif, Mohammad et al.
Braz. J. Pharm. Sci. 2018;54(3):e00040 Page 1 / 12
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902018000300040
A
rt
ic
le
*Correspondence: A. Husain. Department of Pharmaceutical Chemistry, 
School of Pharmaceutical Education and Research, Jamia Hamdard, New 
Delhi-110 062, India. Phone: +91-11-26059681, 26059688, ext. 5647, Mobile: 
+91-989-1116086. Fax: +91-11-16988874. E-mail: drasifhusain@yahoo.com; 
ahusain@jamiahamdard.ac.in
Studies on new substituted pyridazinones: synthesis and biological 
evaluation
Mohammad Asif1, Anita Singh2, Shah Alam Khan3, Asif Husain4*
1Department of Pharmacy, GRD (PG) Institute of Management and Technology, Dehradun, India, 2Department of 
Pharmaceutical Sciences, Kumaun University Campus, Bhimtal, Nainital, (UK) India, 3Department of Pharmacy, Oman 
Medical College, Muscat, Sultanate of Oman, 4Department of Pharmaceutical Chemistry, School of Pharmaceutical Education 
and Research, Jamia Hamdard (Hamdard University), New Delhi, India
We report herein the synthesis and pharmacological evaluation of a new series of 6-aryl-2-(imidazol-
1-yl/1,2,4-triazol-1-yl)-2-methyl-4,5-dihydro-(2H)-pyridazin-3-one (3a-j) as potential anticonvulsant 
and antitubercular agents. The title compounds were prepared by reacting 6-aryl-4,5-dihydro-(2H)-
pyridazin-3-one (2a-e) with formaldehyde and secondary cyclic amine imidazole or 1,2,4-triazole as 
per Mannich reaction. Anticonvulsant activity of pyridazinone derivatives was tested at 50 mg.kg-1 dose 
level against maximal electroshock (MES), isoniazid (INH, 250 mg.kg-1) and pentylenetetrazole (PTZ 
at 80 mg.kg-1) induced seizure methods. Phenytoin sodium (25 mg.kg-1) and sodium valproate (100 mg.
kg-1) were used as reference drugs for comparison purpose. In-vitro antitubercular activity was tested 
by Microplate Alamar Blue assay (MABA) method and the results were compared with clinically used 
antitubercular agents such as INH, Pyrazinamide (PZA) and Streptomycin (STM). None of the screened 
compounds were found to be neurotoxic at a dose level of 100 mg.kg-1. All the screened compounds (3a-j) 
significantly reduced the MES, INH and PTZ induced convulsions and thus showed good anticonvulsant 
activity. The minimum inhibitory concentration (MIC) of the title compounds against M. tuberculosis 
ranged from 1.6 µg/mL to 6.25 µg/mL in comparison to INH, PZA (3.125 µg/mL) and STM (6.25 µg/
mL) which indicated good antitubercular activity. 
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INTRODUCTION
Epilepsy is the most common neurological disorder 
of central nervous system (CNS) characterized by the 
sudden recurrent seizures (Ahsan et al., 2012). The 
seizures, fits or convulsions are caused by sudden 
increase in the electrical activity in the brain. Epilepsy 
is a destructive condition that is quite prevalent in all 
age groups and affects millions of people worldwide. 
Approximately, 1–2% of total world’s population is 
currently suffering from epilepsy and almost two million 
new cases of epilepsy are diagnosed every year. There 
are over twenty drugs available in the market for the 
treatment of epilepsy but only six or seven out of them are 
preferred in clinical setting. It has been reported that the 
convulsions of approximately 25% of epileptic patients 
are inadequately controlled by the current drug therapy 
(Deng et al., 2010; Edafiogho et al., 2009). Despite the 
development of several new anticonvulsant drugs, the 
treatment of epilepsy still remains inadequate. 
Antiepileptic drugs (AED) should be prescribed and 
used carefully as these drugs can cause severe side effects 
eventually affecting quality of life. Their use is associated 
with significant dose-related toxicity and adverse 
effects such as tremor, blurred vision, neurotoxicity and 
sometimes death due to either hepatic damage or from 
aplastic anaemia (Ghogare et al., 2010; Gunia et al., 2010; 
Hu et al., 2010).
An anticonvulsant drug acts by multiple mechanism 
involving interaction with more than one specific target. 
Therefore, evaluation of anticonvulsant drugs mostly 
includes in vivo screening tests employing different 
seizure models which have been developed to investigate 
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the diverse mechanisms of action of potential drug 
molecules. There is diversity in the structures of currently 
available drugs for the management of epilepsy like 
phenytoin, lamotrigine, phenobarbitone, rufinamide 
and carbamazepine. The anticonvulsant properties 
of these drugs could possibly be attributed to the 
presence of diverse group of chemical functionalities like 
hydrazones (=N-NH-), amides (-CONH2), and carbamides 
(-NHCONH-) etc., present in these molecules.
Tuberculosis (TB), caused by Mycobacterium 
tuberculosis, is a highly infectious disease affecting 
approximately one third of the world’s population. It kills 
almost 2 million people each year across the globe. Despite 
the availability of antitubercular drugs since 1950s, TB 
continues to be one of the top three infectious diseases 
of global concern (Sandhu, 2011). The current situation 
is worsened by HIV epidemic that has resulted in high 
incidence rates of developing active TB, an increased 
prevalence of multi-drug resistant TB (MDR-TB) and an 
ever increasing emergence of extensively drug-resistant 
(XDR) TB (Asif, 2012a). The development of resistance 
makes TB difficult to cure with the available drugs which 
particularly interfere and inhibit cell processes of growing 
bacteria. Therefore, there is an urgent need to develop new 
TB drugs having both bactericidal as well as sterilizing 
activity against TB bacillus (Asif, 2012b). Sincere efforts 
should be made to discover and develop anti TB drugs 
that are: able to shorten the duration of therapy; active 
against resistant TB i.e. MDR and XDR strains; free 
from hepatotoxicity; having easy to metabolize chemical 
structures and which can be taken along with HIV 
medications, etc.
The pyridazinones belong to an important class 
of heterocyclic compounds which have been reported 
to exhibit several useful biological activities such as 
antibacterial, antifungal, antidepressant, antihypertensive, 
anti platelets, cardio tonic, diuretics, anti-HIV, anticancer, 
antiulcer and other useful anticipated activities (Akahane, 
Katayama, Mitsunaga, 1999; Amin et al., 2010; Asif, 
2012a; Demirayak, Karaburun, Beis, 2004; Khokra et al., 
2015). Some pyridazinone compounds are used as drugs 
like indolidan, pimobendan, bemoradan, primobendan, 
levosimendan and azanrinone (cardiovascular agents), 
minaprine (ant idepressant) ,  emorfazone (ant i-
inflammatory) (Asif, 2012b). Literature revealed that 
various pyridazinone analogues are active against epilepsy 
(Hallot et al., 1986; Siddiqui et al., 2006; Xu et al., 1991) 
and Mtb (Islam, Siddiqui, Rajesh, 2008; Siddiqui, Mishra, 
Shaharyar, 2010). 
Isoniazid (INH) generated convulsions and anti-TB 
effects could be related to its structure which contains an 
aromatic pyridinyl ring and a free carbonyl hydrazide 
group at para position (Figure 1). Similarly, it has been 
reported that aryl pyridazinone compounds bearing 
an aromatic group at 6-position and a cyclic carbonyl 
hydrazide group as a part of its ring system exhibits 
anticonvulsant and antitubercular activities (Asif, Singh, 
Bilkanti, 2013). Thus, on the basis of structural similarities 
between INH and aryl pyridazinone, we deduced 
that cyclic carbonyl hydrazide group is necessary for 
anticonvulsant activity (ACA) in pyridazine ring while 
open carbonyl hydrazide group is essential for anti-TB 
activity. These structural similarities encouraged us to 
prepare new compounds having both functionalities 
in search of compounds exhibiting both antiepileptic 
and antitubercular properties (Bialer, 2006; Gerlach, 
Krajewski, 2010; Asif, Singh, 2015). 
The aryl-pyridazinone moiety is made up of several 
smaller functional groups exhibiting anti-TB activity 
(Figure 2). These aryl-pyridazinones contain carbonyl 
hydrazide group in cyclic structure and aryl group, 
similar groups are also present in well known anti-TB 
drug, isoniazid. Considering the 6-aryl-pyridazinone 
moiety as the pharmacophoric group for the biological 
activity, we have synthesized some 6-aryl-2-(imidzol-1-
yl or (1,2,4-triazol-1-yl)-2-methyl-pyridazin-3(2H)-one 
derivatives and evaluated them for anticonvulsant activity 
by maximum electro shock (MES), isoniazid (INH) 
FIGURE 1 - Structure similarities of Aryl-pyridazinone compounds and anti-TB drug Isoniazid.
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and subcutaneous pentylenetetrazole (scPTZ) induced 
convulsion methods and in-vitro antitubercular activity 
by microplate alamar blue dye assay (MABA) method.
MATERIAL AND METHODS
Chemistry
All the chemicals used were of high purity and 
were purchased from Central Drug House (CDH), Loba 
Chem and Hi-media. 6-(aryl)-2-(imidazol-1-yl/1,2,4-
triazol-1-yl-methyl)-4,5- dihydro (2H)-pyridazin-3-one 
derivatives were prepared according to the Scheme 1. 
The Friedel–Craft acylation of substituted aromatic 
compound with succinic anhydride in presence of 
anhydrous aluminum chloride (AlCl3) yielded the 
substituted 4-oxo-butyric acid (1a-e). The resulting aroyl 
propionic acids on reaction with hydrazine hydrate gave 
the 6-aroyl-pyridazinones (2a-e). 6-aryl-pyridazinones 
(2 mM) were mixed with cyclic secondary amine 
(imidazole and 1,2,4-triazole; 2 mM), formaldehyde 
(40 mM) and refluxed on a water bath for 8-12 h to obtain 
the final compounds (3a-j) by Mannich reaction. An open 
tube capillary method was used to determine melting 
point of synthesized compounds and are uncorrected. 
Purity of the compounds was checked by silica gel G 
coated thin layer chromatography (TLC) plates. The 
spots on TLC plates were detected under UV light 
and by exposing to iodine vapors. The FT-IR spectra 
were recorded on Bio-rad FTS-135 spectrophotometer 
using KBr pellets; 1H NMR and 13CNMR spectra were 
recorded on Bruker Spectrospin DPX 300 MHz using 
DMSO-d6 and CDCl3 as solvent. Chemical shift values 
are reported as δ (ppm) and coupling constants (J values) 
are expressed in Hz with reference to tetramethyl silane 
(TMS). Mass spectrometry for title compounds was 
performed on a JEOL JMS-D 300 instrument fitted with 
a JMS 2000 data system at 70 eV.
Synthesis of aroyl propionic acid (1a-e)
All the aroyl propionic acids (1a-e) were synthesized 
as per the previously reported procedure with slight 
adjustment in temperature of reaction, duration of reaction 
and by using nitrobenzene as a solvent (Siddiqui, Mishra, 
Shaharyar, 2010). Briefly, an equimolar quantity of 
aromatic compound (toluene, naphthalene, ethylbenzene, 
xylene, biphenyl; 0.1 mol) and succinic anhydride 
(0.1 mol) were dissolved in nitrobenzene and were 
refluxed in presence of anhydrous aluminium chloride 
(0.1125 mol) on a water bath for two- four hours. The 
excess solvent was removed by steam distillation. It was 
FIGURE 2 - Concept of pyridazinones as anticonvulsants and 
as anti-TB agents.
SCHEME 1- Synthetic route for the synthesis of target compounds (3a-j)
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purified by dissolving in sodium hydroxide solution, 
filtering, followed by the addition of hydrochloric acid. 
The solid mass so obtained was filtered, washed with cold 
water, dried and re-crystallized from ethanol to obtain 
aroyl propionic acid.
4-p-tolyl-4-oxobutyric acid (1a)
mp 122-123°C; 67 % yield. IR: (KBr, cm-1): 1659 
(CO), 2996 (CH), 3413 (OH); 1H-NMR (DMSO-d6, δ 
ppm): 2.38 (s, 3H, CH3), 2.78 (t, 2H, CH2), 2.99 (t, 2H, 
CH2), 7.26 (t, 2H, Ar-H3’,5’), 12.15 (s,1H, COOH); MS 
(m/z): 193 (M++1; C11H12O3).
4-naphthalen-2-yl-4-oxobutyric acid (1b)
mp 116-117 °C; 62% yield. IR: (KBr, cm-1): 1705 
(CO), 3096 (CH), 3401. (OH); 1H-NMR (DMSO-d6, δ 
ppm): 2.80 (t, 2H, CH3), 3.11 (t, 2H, CH2), 7.26-8.3 (m, 
7H, Ar-H), 12.15 (s, 1H, COOH); MS (m/z):228 (M+; 
C14H12O3).
4-p-ethylphenyl-4-oxobutyric acid (1c)
mp 138-140 °C; 73% yield. IR: (KBr, cm-1): 1698 
(CO), 2990.6 (CH), 3402.6 (OH); 1H-NMR (DMSO-d6, 
δ ppm): 1.24 (t, 3H, CH3), 2.79 (q, 2H, CH2), 2.40 (t, 2H, 
CH3), 3.20 (t, 2H, CH2), 7.24 (m, 2H, Ar-H3’,H5’), 7.84 
(m, 2H, Ar-H2’, H6’), 12.15 (s, 1H, COOH); MS (m/z): 
207 (M++1; C12H14O3).
4(3,4-dimethylphenyl)- 4-oxobutyric acid (1d)
mp 145 °C; 45% yield. IR: (KBr, cm-1): 1718 (CO), 
3105.6 (CH), 3410. (OH); 1H-NMR (DMSO-d6, δ ppm): 
2.35 (s, 6H, 2xCH3), 2.80 (t, 2H, CH2), 3.10 (t, 2H, CH2), 
7.20-7.59 (m, 3H, Ar-H2’, H3’, H5’), 12.10 (s, 1H, 
COOH); MS (m/z): 207 (M++1; C12H14O3). 
4-biphenyl 4-oxobutyric acid (1e)
mp 127-128 °C; 63% yield. IR: (KBr, cm-1): 1720 
(CO), 2905.6 (OH), 3410.6 (NH); 1H-NMR (DMSO-d6, 
δ ppm): 2.35 (s, 3Hx2, CH3), 2.84 (t, 2H, CH3), 3.0 (t, 2H, 
CH2), 7.22-8.50 (m, 9H, Ar-H), 12.10 (s, 1H, COOH); MS 
(m/z): 255 (M++1; C16H14O3).
Synthesis of 6-aryl 2,3,4,5-tetrahydropyridazin-3-one 
(2a-e) 
These compounds were synthesized as per the 
reported method (Islam, Siddiqui, Rajesh, 2008; Siddiqui, 
Mishra, Shaharyar, 2010).
6-(p-tolyl-4,5-dihydro(2H)- pyridazin-3-one (2a)
mp 151-153 °C, yield 70 %, Rf value 0.70, 
IR:(KBr,cm-1):1659 (C=O), 3217 (NH), 1511 (C=N); 
1HNMR (DMSO-d6, δ, ppm): 2.36 (s,3H,CH3), 2.60 (t, 
2H, CH2), 2.97 (t, 2H, CH2), 7.27 (t, 2H, Ar-H3’,5’), 7.65 
(d,2H, Ar-H2’,6’), 8.80 (s, H, NH); MS (m/z): 188 (M+; 
C11H12N2O).
6-(naphthalen-2-yl)-4,5- dihydro(2H)-pyridazin-3-one 
(2b)
mp 165-166 °C; yield 75 %, Rf value 0.65, IR: (KBr, 
cm-1): 3094 cm-1 (CH), 1708 cm-1 (C=O), 1617 cm-1 (C=C). 
1HNMR (DMSO-d6) ppm 3.1 (t, 2H, CH2), 3.36 (t, 2H, 
CH2), 7.29- 8.2 (m, 7H, Ar-H), 8.82 (s, H, NH); MS (m/z): 
224 (M+; C14H12N2O)
6-(4-ethylphenyl)-4,5- dihydro(2H)-pyridazin-3-one 
(2c)
mp 119-122 °C; yield 70 %, Rf value 0.73, IR: (KBr, 
cm-1): 1666 (C=O), 3428 (NH), 1595 (C=N); 1HNMR 
(DMSO-d6, δ, ppm): 1.24 (t, 3H, J=7Hz, CH3-CH2-), 
1.59(q, 2H, CH3-CH2-s), 2.64(m, 2H, CH2), 3.01 (m, 2H, 
CH2), 7.26 (d, 2H, Ar-H3’,5’) 7.65 (d, 2H, Ar-H2’,6’), 8.54 
(s, H, NH); MS (m/z): 202 (M+; C10H11NO3).
6-(3,4-dimethylphenyl)-4,5- dihydro(2H)-pyridazin-3-
one (2d)
mp 162-163 °C, yield 50 %, Rf value 0.50, IR: (KBr, 
cm-1): 1668 (C=O), 3220 (NH), 1508 (C=N); 1HNMR 
(DMSO-d6, δ, ppm): 1.36 (s, 6H, 2xCH3), 2.65 (t, 2H, 
CH2), 3.01 (t, 2H, CH2), 7.47 (d, H, ArH5’), 7.65 (d, H, 
Ar-H6’), 7.51 (s, H, Ar-H2’), 8.70 (s, H, NH); MS (m/z): 
202 (M+; C12H14N2O).
6-(1,1’-biphenyl-4-yl)-4,5- dihydro(2H) pyridazin-3-one 
(2e)
mp 240-243 °C, yield 90 %, Rf value 0.72, IR: (KBr, 
cm-1): 3248 (NH), 1700 (C=O); 1HNMR (DMSO-d6, 
δ, ppm): 2.7 (t, 2H, CH2), 2.98 (t, 2H, CH2), 7.39-7.83 
(m, 9H, Ar-H), 9.94 (s, 1H, NH); MS (m/z): 250 (M+; 
C16H14N2O).
General procedure for the synthesis of 6-aryl-2-
(imidzol-1yl / 1,2,4-triazol-1-yl)-2-methyl-4,5- 
dihydro(2H)-pyridazin-3-one (3a-j)
A mixture of 6-aryl4,5-dihydropyridazin-3-one 
(2a-e; 0.002 mol), formaldehyde 37–41% (0.04 mol) and 
an appropriate secondary amine (0.002 mol) in ethanol 
(50 mL) was allowed to stand overnight at the room 
temperature and then refluxed for 8-12 h. The progress of 
reaction was monitored by TLC. The product which was 
left after removal of most of the solvent was poured into 
crushed ice. The solid so obtained was crystallized from 
ethanol to afford pure solid product.
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2-(1,2,4)-triazol-1-yl-methyl-6-(4-ethylphenyl)-4,5- 
dihydro (2H)-pyridazin-3-one (3a)
Yield: 50%; mp 140–142 °C; IR (KBr, cm-1): 2995 
(CH), 1670 (C=O). 1H NMR (CDCl3) δ (ppm): 1.2 (t, 3H, 
CH3), 2.5(q, 2H, CH2), 2.6 (t, 2H, C–CH2), 3.0 (t, 2H, 
-CH2–CO), 5.3 (s, 2H, –N–CH2–N–), 7.3–7.9 (m, 6 H, 
Ar–H); 13C NMR (CDCl3) δ (ppm): 15.5 (CH3), 25.5- 65.2 
(4XCH2), 125.1-152.8 (Ar-C), 173.5 (C=O); MS (m/z): 
283 (M+; C15H17N5O).
6-biphenyl-4-yl-2-imidazol-1-yl-methyl-4,5- 
dihydro(2H)-pyridazin-3-one (3b)
Yield: 50%; mp 140–142 °C; IR (KBr, cm-1): 2990 
(CH), 1678 (C=O). 1H NMR (CDCl3) δ (ppm): 2.6 (t, 2H, 
C–CH2), 3.11(t, 2H, CH2–CO), 5.27 (s, 2H, –N–CH2–N–), 
7.36–8.14 (m, 11 H, Ar–H); 13C NMR (CDCl3) δ (ppm): 
28.4, 33.4, 67.2 (3XCH2), 125.9-157.1 (Ar-C), 176.1 
(C=O); MS (m/z): 330 (M+; C20H18N4O).
6-biphenyl-4-yl-2(1,2,4)triazol-1-yl-methyl-4,5- 
dihydro(2H) -pyridazin-3-one (3c)
Yield: 61%; mp 145–146 °C; IR (KBr, cm-1): 2992 
(CH), 1690 (C=O), 1590 (C=N). 1H NMR (CDCl3) δ 
(ppm): 2.6 (t, 2H, C–CH2), 2.96 (t, 2H, CH2–CO), 5.26 
(s, 2H, –N–CH2–N–), 7.40–7.81 (m, 12 H, Ar–H); ); 13C 
NMR (CDCl3) δ (ppm): 26.1- 65.2 (3XCH2), 127.2-152.5 
(Ar-C), 173 (C=O); MS (m/z): 331 (M+; C19H17N5O).
6-(4-ethyl-phenyl)-2-imidazol-1-yl-methyl-4,5- 
dihydro(2H)-pyridazin-3-one (3d)
Yield: 53%; mp 135–137 °C; IR (KBr, cm-1): 3005 
(CH), 1685 (C=O). 1H NMR (CDCl3) δ (ppm): 1.2 (t, 3H, 
CH3), 2.5(q, 2H, CH2), 2.68 (t, 2H, C–CH2), 3.0 (t, 2H, 
CH2–CO), 5.3 (s, 2H, –N–CH2–N–), 7.38–7.73 (m, 7H, 
Ar–H); 13C NMR (CDCl3) δ (ppm): 18.2 (CH3), 27.4, 29.5, 
33.2, 65.6 (4XCH2), 128.1-156.1 (Ar-C), 175.8 (C=O); 
MS (m/z): 282 (M+; C16H18N4O).
2-imidazol-1-yl-methyl-6-naphthalen-2-yl-4,5- 
dihydro(2H)-pyridazin-3-one (3e)
Yield: 47%; mp 145–147 °C; IR (KBr, cm-1): 3015 
(CH), 1694 (C=O). 1H NMR (CDCl3) δ (ppm): 2.64 (t, 2H, 
C–CH2), 2.95 (t, 2H, CH2–CO), 5.28 (s, 2H, –N–CH2–N–), 
6.8–8.3 (m, 10 H, Ar–H); 13C NMR (CDCl3) δ (ppm): 27.6, 
35.1, 65.2 (3XCH2), 123.1-155.2 (Ar-C), 175.2 (C=O); 
MS (m/z): 304 (M+; C18H16N4O).
6-(3,4-dimethyl-phenyl)-2-imidazol-1-yl-methyl-4,5- 
dihydro(2H)-pyridazin-3-one ( 3f)
Yield: 40%; mp 131–133 °C; IR (KBr, cm-1): 2990 
(CH), 1690 (C=O). 1H NMR (CDCl3) δ (ppm): 2.29 (s, 
6H, 2xCH3), 2.6 (t, J = 7.5, 2H, C–CH2), 3.0 (t, J=7.5, 
2H, CH2–CO), 5.3 (s, 2H, -N–CH2–N–), 6.8–7.5 (m, 6H, 
Ar–H); 13C NMR (CDCl3) δ (ppm): 15.5 (2XCH3), 27.4, 
33.4, 65.1 (3XCH2), 125.1-155.9 (Ar-C), 175.2 (C=O); 
MS (m/z): 282 (M+; C16H18N4O).
2-(1,2,4-triazol-1-yl-methyl)-6-(3,4-
dimethylphenyl)-4,5- dihydro(2H)-pyridazin-3-one (3g) 
Yield: 55%; mp 126–128 °C; IR (KBr, cm-1): 3005 
(CH), 1685 (C=O), 1585 (C=N). 1H NMR (CDCl3) δ 
(ppm): 2.32 (s, 6H, 2xCH3), 2.66 (t, J = 7.6, 2H, C–CH2), 
3.0 (t, J= 7.7, 2H, CH2–CO), 5.30 (s, 2H, –N–CH2–N–), 
7.00–7.83 (m, 5H, Ar–H); ); 13C NMR (CDCl3) δ (ppm): 
14.5 (2XCH3), 27.5, 35, 65.5 (3XCH2), 128.1-155 (Ar-C), 
175 (C=O); MS (m/z): 283 (M+; C15H17N5O).
6-naphthalen-2-yl-2-(1,2,4)-triazol-1-yl-methyl-4,5- 
dihydro(2H)-pyridazin-3-one (3h)
Yield: 40%; mp 141–144 °C; IR (KBr, cm-1): 3015 
(CH), 1686 (C=O). 1H NMR (CDCl3) δ (ppm): 2.68 (t, 2H, 
C–CH2), 2.98 (t, 2H, CH2–CO), 5.26 (s, 2H, –N–CH2–N–), 
7.3–8.3 (m, 9H, Ar–H); 13C NMR (CDCl3) δ (ppm): 27.2, 
34.2, 67.1(3XCH2), 125.1-154.9 (Ar-C), 176.1 (C=O); MS 
(m/z): 305 (M+; C17H15N5O).
6-p-tolyl-2-(1,2,4)-triazol-1-yl-methyl-4,5- dihydro(2H) 
-pyridazin-3-one (3i) 
Yield: 52%; mp 138–140 °C; IR (KBr, cm-1): 2995 
(CH), 1676 (C=O). 1H NMR (CDCl3) δ (ppm): 2.31 (s, 
3H, CH3), 2.66 (t, 2H, C–CH2), 3.0 (t, 2H, CH2–CO), 5.3 
(s, 2H, –N–CH2–N–), 6.87–7.83 (m, 6H, Ar–H); 13C NMR 
(CDCl3) δ (ppm): 21.1 (CH3), 27.2, 34.9, 66.1 (3XCH2), 
128.5-155.5 (Ar-C), 174.8 (C=O); MS (m/z): 269 (M+; 
C14H15N5O).
2(imidazol-1-yl-methyl)-6-p-tolyl-4,5- dihydro(2H)-
pyridazin-3-one (3j) 
Yield: 45%; mp 122–123 °C; IR (KBr, cm-1): 3050 
(CH), 1700 (C=O). 1H NMR (CDCl3) δ (ppm): 2.33 (s, 
3H, CH3), 2.66 (t, 2H, C–CH2), 3.0 (t, 2H, CH2–CO), 5.3 
(s, 2H, –N–CH2–N–), 6.88–7.83 (m, 7H, Ar–H); 13C NMR 
(CDCl3) δ (ppm): 20.2 (CH3), 27.7, 33.7, 65.1 (3XCH2), 
122.5-151.9 (Ar-C), 173.5 (C=O); MS (m/z): 268 (M+; 
C15H16N4O).
Pharmacology
The in vivo anticonvulsant activity was investigated 
by using Swiss albino mice (20–30 g) of either sex. The 
experimental animals were provided standard diet, free 
access to food and water and were housed in plastic cages 
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maintained at room temperature (25–30 °C). The animals 
were divided into the groups having 5 animals in each. A 
prior approval for conducting the study was obtained from 
the Institutional Animal Ethics Committee (IAEC) of GRD 
(PG) IMT, Dehradun, India.
Neurotoxicity screening
Rotarod performance test was used to measure 
the synthesized molecules’ interference with the motor 
coordination activity. For this purpose, mice were 
acclimated and trained to stay on the rotarod prior to the 
experiment. The rod having a diameter of 3.2 cm was 
operated at 10 rotations min-1. Normally a mouse could 
maintain equilibrium on the rotating rod by using its fore 
limbs and hind limbs for prolonged period of time. The 
title compounds 3a-j (50 and 100 mg.kg-1 body mass) 
were injected intraperitoneally (i.p.) and their effect on 
impairment of motor activity was measured. Neurotoxicity 
of tested compounds was signaled by the inability of the 
animal to maintain equilibrium (balance) on the rod for 
at least one minute in each of the three attempts. Mice 
lose their balance due to the relaxation of skeletal muscle 
caused by the drug (Sethi et al., 2011). 
Anticonvulsant screening
Maximum electroshock seizure (MES) method
The anticonvulsant screening of the test compounds 
(3a-j) was assessed as per the standard drug development 
protocol for anticonvulsant agents. Albino mice having 
previously received the test/standard drug (50 mg.kg–1 
body mass) by i.p. route were stimulated through 50 mA 
current of corneal electrodes for 0.20 sec at a pulse of 
60 Hz. Anticonvulsant activity was indicated by the 
abolition of the hind limb tonic extension spasm and 
was recorded (Kulkarni, 1999; Porter et al., 1984). The 
standard drugs; sodium valproate (100 mg.kg–1) and 
phenytoin sodium (25 mg.kg–1) were used for comparing 
the anticonvulsant activity.
Isoniazid (INH) induced seizures method 
To evaluate the anticonvulsant activity of the 
synthesized compounds by Isoniazid (INH) induced 
seizures test method, the compounds were administered 
in mice at a dose of 50 mg.kg–1 i.p. After 30 min of the test 
drug administration, all mice received an i.p. injection of 
INH (250 mg.kg–1). The sequence of seizure latency, no. 
of seizures and % protection were studied. The reference 
drugs used in this model for comparison purpose were 
sodium valproate (100 mg.kg–1) and phenytoin sodium 
(25 mg.kg–1) (Porter et al., 1984; Sethi et al., 2011).
Pentylenetetrazole (PTZ) induced seizures method
To assess the anticonvulsant activity of the synthesized 
compounds by Pentylenetetrazole (scPTZ) induced seizures 
test method, mice were injected with test drugs 50 mg.kg–1 
i.p. After 30 min, all mice received subcutaneous (s.c.) 
injection of scPTZ at dose of 80 mg.kg–1. The sequence 
of seizure latency, no. of seizures and % protection were 
studied. The standard drugs used in this model were sodium 
valproate (100 mg.kg–1) and phenytoin sodium (25 mg.kg–1) 
(Porter et al., 1984; Sethi et al., 2011).
Strychnine (STR) induced seizures method
For the evaluation of anticonvulsant activity 
against strychnine (STR) induced convulsions, the same 
process was implemented as mentioned in PTZ induced 
convulsions. Instead, strychnine sulphate (STR-3 mg.kg–1 
i.p.) was used for inducing convulsions (Porter et al., 1984; 
Sethi et al., 2011). 
Anti-TB activity by using Microplate Alamar Blue Dye 
test 
The anti-tubercular activity of synthetic compounds 
(3a-j) was tested against M. tuberculosis using a non 
toxic microplate Alamar Blue screening assay (MABA) 
technique. A thermally stable reagent is used in rapid 
and safer MABA technique which demonstrates good 
correlation and proportionality with BACTEC radiometric 
assay method. Briefly, 200 µL of sterile deionized water 
was added to all outer perimeter wells of sterile 96 wells 
plate to reduce the evaporation of medium from the test 
wells during incubation. A measured 100 µL of the Middle 
brook 7H9 broth was added to the 96 wells plate and was 
used directly to prepare the serial dilution of compounds. 
The final drug concentrations of 3a-j were kept between 
100 to 0.2 µg/mL for determination of MIC. The sealed 
and covered plates with parafilm were incubated at 37 ºC 
for five days. After five days, 25 µL of freshly prepared 
1:1 mixture of Almar Blue reagent and 10% tween 80 
were added to the plate and again incubated for 24 h. 
Appearance of blue color in the well was inferred as 
absence of bacterial growth, whereas a pink color was 
scored as growth. The lowest concentration which 
prevented color change from blue to pink was considered 
as the MIC (Lourenco et al., 2007). 
Statistical analysis
All the tests were performed in triplicate and results 
are expressed as mean ± S.E.M. One-way analysis of 
variance (ANOVA) followed by Tukey’s test was used 
to determine the statistical significance among groups. A 
p-value (< 0.05) was considered statistically significant. 
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RESULTS AND DISCUSSION
The chemical structures of prepared pyridazinone 
compounds (3a-j) (Table I) were characterized on the 
basis of spectral data. The IR spectra revealed presence 
of C=O and CH groups. The 1H NMR showed singlet for 
methyl and two signals with appropriate multiplicities for 
ethyl groups attached to phenyl ring and two triplets for 
methylene protons at 4th and 5th (CH2-CH2) of pyridazinone 
ring, respectively. The singlet at δ 5.26-5.30 is due to a 
methylene group flanked by two nitrogen atoms. In the 
aromatic region, most of the compounds showed multiple 
peaks at 7-8 δ value. The 13C NMR and mass spectral data 
were also found in consistent with the chemical structure 
of synthesized compounds. 
The final pyridazinone compounds (3a-j) were 
screened for the anticonvulsant activity by maximum 
electro shock (MES, 50 mg.kg-1), isoniazid (INH, 
250  mg kg-1), and pentylenetetrazole (scPTZ, 80 mg.kg-1) 
induced seizures methods in mice. The results are shown 
in Table II-V and have been compared with the standard 
drugs, sodium valproate and phenytoin sodium. The title 
compounds (3a-j) were also tested for antitubercular 
activity by microplate alamar blue dye assay (MABA) 
method and the results are presented in Table VI. 
None of the tested compounds showed neurotoxicity 
or impairment of motor coordination activity in mice 
by rotarod method at dose level of 100 mg.kg–1. The 
MES, scPTZ and INH seizure models represent the three 
animal seizure models which are most reliable and thus 
routinely used in the screening of a new chemical entity 
as anticonvulsant agent. 
In the present study, the MES seizure model involving 
extensor phase, which is similar to grand mal epilepsy, was 
used for preliminary screening of compounds 3a-j. It can 
be seen that all the compounds (3a-j) were able to prevent 
seizure spread in MES test method (Table II). Amongst all 
the compounds, six compounds 3e, 3c, 3b, 3i, 3h and 3g 
produced conspicuous anticonvulsant activity showing 
protection against MES-induced seizures at the dose of 
50 mg.kg–1. These six compounds are more potent than 
standard drug phenytoin sodium at the dose of 25 mg.
kg–1, remaining compounds showed less protection than 
phenytoin sodium. It was interesting to note that majority of 
the screened compounds were observed to be more potent 
in comparison to the reference drug, sodium valproate at 
the dose of 100 mg.kg–1. Thus, it could be suggested that 
the aryl-pyridazinone derivatives produce their action by 
inhibiting the voltage-gated ion channels (particularly 
sodium channels) analogous to a sodium channel inhibitor 
phenytoin which is quite active in MES model. 
Most of the synthesized compounds (3a-j) exhibited 
protection against INH induced convulsions. The 
compounds after administration increased the onset of 
convulsion time from 36.2-47.6 min, reduced the number 
of convulsions (2.8 to 1.2) and increased the number of 
recovery of animals (80-100) in comparison to control 
group (26.16 min, 3.2 and 0 respectively). Compounds 3f, 
3i, 3j, 3c and 3d are noted to be more effective than the 
rest of the compounds. Compounds 3f showed maximum 
activity while compound 3e showed the lowest activity 
among all the synthetic compounds (3a-j) (Table III). 
TABLE I - Structures of 6-aryl-2-(substituted amino-1yl)-2-
methyl-4,5- dihydro (2H)-pyridazin-3-one derivatives (3a-j)
 
General Structure of 6-aryl-4,5-dihydro (2H) pyridazin-3-
one
Compounds R1 R2 R3
3a
 
C2H5 H
3b
  
H
3c
  
H
3d
 
C2H5 H
3e
  
3f
 
CH3 CH3
3g
 
CH3 CH3
3h
  
3i
 
CH3 H
3j
 
CH3 H
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TABLE II - Anticonvulsant activities of 6-aryl-2-(imidazol-1-yl / 1,2,4-triazol-1-yl)-2-methyl-4,5- dihydro (2H)-pyridazin-3-one 
against maximum electro shock (MES) induced method
Compounds Flexion (in sec)
Extensor 
(in sec)
Clonus 
(in sec)
Stupor 
(in sec)
Recovery 
(in sec) Recovery
Control 6.8±0.10 16.2±0.50 16.5±0.29 29.3±1.7 225.4±9.61 00
3a 6.4±0.50 γ3 4.4±0.50c 15.2±1.063 21.8±3.8 γ 120.6±4.431a 100
3b 8.2±1.02γ3c 2.4±0.50 γc 20.5±1.63c 20.3±2.6γ 117.3±7.52b 80
3c 12.0±0.70γ3c 2.4±0.50 γc 20±1.83c 18±0.91γ 78±7.45c 80
3d 12.4±0.81γ3c 4.0±0.83c 9.0±1.0c 49±7.0 64.8±7.36 γ3c 80
3e 4.6±1.32b 2.0±0.63 γc 8.5±0.50c 15±3.0 67.2±5.99c 100
3f 9.2±1.46 γ3b 6.0±1.153c 13.5±1.53b 18±2.0 γ3 39±13.06c 100
3g 2.2±0.37c 3.0±1.0 γc 11±1.0 β3c 21±3.0 γ3 40.8±7.541b 100
3h 6.8±0.86 γ3 2.8±0.37 γc 9.0±1.0c 14±2.0 35.8±8.05c 100
3i 5.4±0.74 α3 2.8±0.47γc 14±1.0a 16±2.0 γ3 41.8±9.14c 80
3j 2.8±0.58c 4.5±0.50c 7.0±1.0c 13.5±1.5 63.3±4.9c 80
Phenytoin Sod 3.1±0.20 3.3±0.56 6.7±0.51 14.2±0.82 25.0±2.1 100
SodValproate 3.6±0.82 5.3±0.68 7. 6±1.24 18.8±2.43 26±3.31 80
Standard drug: Phenytoin sodium (25mg.kg-1) and sodium valproate (100 mg.kg-1), Tested drugs: Synthesized compounds 3a-g 
(50 mg.kg-1), Control group: 0.5 % Carboxyl methyl cellulose (CMC) in distilled water; n=5 (No. of animals in each group); *Value 
represents mean ± S.E.M. aP< 0.05, bP< 0.01 and cP< 0.001 when compared to control group; αP< 0.05, βP< 0.01 and γP< 0.001 when 
compared to standard drug sodium valproate; 1P< 0.05, 2P< 0.01 and 3P< 0.001 when compared to standard drug phenytoin sodium
In PTZ induced convulsion model, compounds 3a, 
3d, 3j, 3g and 3h showed good anticonvulsant activity. 
The control group showed an onset of convulsion, 
number of convulsions and recovery as 7.6 min, 1.8 and 0 
respectively. In contrast, groups treated with the synthetic 
compounds had the onset of convulsions ranging from 
13.4 to 16.6 min and indicate protection. It can also be seen 
from the results that the synthesized compounds decreased 
the number of convulsions (1-1.6) and lead to the better 
recovery of animals (60-100%). Compound 3a (16.6 min) 
showed the highest activity and compound 3b (13.4 min) 
showed the lowest activity amongst all the screened 
compounds (3a-j) in terms of onset of convulsions 
(Table IV). Similarly, compound 3h, 3i (1.0), 3a, 3b, 3c, 
3f, 3j (1.2) produced lower number of convulsions in 
comparison to standard drug sodium valproate (1.3). The 
recovery rate of 3h, 3i and 3j was 100% while it was found 
to be 60% for 3g. However, the title compounds were 
having a weak anticonvulsant spectrum in comparison to 
Phenytoin sodium. 
In STR-induced convulsions (3mg.kg-1), compounds 
(3a-j) at 50 mg.kg-1 dose level did not show any significant 
anticonvulsant activity (Table V). Compounds 3a-j did not 
show any significant decrease in the number of convulsions 
(2.6-3.0) and onset of convulsions (1.92-2.96) induced 
by the administration of STR in comparison to control 
(3.17 and 1.5 respectively). It is well know that seizures 
produced by PTZ and INH are due to the inhibition of 
TABLE III - Anticonvulsant activities of 6-aryl-2-(imidazol-1-yl 
/1,2,4-triazol-1-yl)-2-methyl-4,5- dihydro (2H)-pyridazin-3-one 
against isoniazid (INH) induced method
Compounds Onset of convulsion
No. of 
convulsion Recovery
3a 36.2±9.27γa 1.7±0.25 100
3b 46±4.51γc 2.6±0.24 80
3c 45.6±4.87γc 2.8±0.20 80
3d 46.6±3.21γc 2.2±0.37 100
3e 35.2±8.98γ 2.75±0.25 100
3f 47.6±1.6γc 2.2±0.37 100
3g 41.8±2.03γc 2.0±0.44 100
3h 48±1.7γc 2.8±0.20 80
3i 46.6±4.04γc 2.4±0.40 100
3j 47.2±4.58γc 2.2±0.20 100
Sodium valproate 130.2 ± 2.15 1.2±0.20 100
Phenytoin sodium 0.00 0.00 100
Control 26.16±0.94 3.2±0.20 00
Standard drug: Phenytoin sodium (25 mg.kg-1) and sodium 
valproate (100 mg.kg-1), Tested drugs: Synthesized compounds 
3a-j (50 mg.kg-1), Control group: INH-250mg.kg-1+0.5% 
carboxyl methyl cellulose (CMC) in distilled water; n=5 (No. 
of animals in each group); *Value represents mean ± S.E.M. 
aP< 0.05, bP< 0.01 and cP< 0.001 when compared to control 
group; αP< 0.05, βP< 0.01 and γP< 0.001 when compared to 
standard drug sodium valproate
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γ-aminobutyric acid (GABA) neurotransmission in the 
brain (Kalso, 2005; Dalkara, Karakurt, 2012; Zulini, 
Fantini, Rivara, 2012). GABA is the primary inhibitory 
neurotransmitter in the central nervous system, and 
its deficiency or inhibition is linked to genetic and 
acquired epilepsy (Gajcy, Lochynski, Librowski, 2010; 
Dalkara, Karakurt, 2012). While increased GABAergic 
neurotransmission inhibit or decrease seizure propensity. 
It was observed that compounds 3a-j thoroughly inhibited 
the clonic seizures, tonic seizures and lethality induced by 
sc-PTZ and INH, while the reference drugs also inhibit 
the clonic seizures induced by sc-PTZ and INH (Table III 
and Table IV). Those compounds which exhibited high 
anticonvulsant activity in the MES and sc-PTZ models 
are most likely to possess a good anticonvulsant profile 
and can be explored further for drug development. The 
STR (glycine antagonist) test is known to be sensitive 
to antagonize glycine (Dutertre, Becker, Heinrich Betz, 
2012), which suggested that compounds 3a-j may not 
inhibit the glycine concentration in the brain.
Possible mechanisms of anticonvulsant compounds
The commonly used in vivo models for preclinical 
discovery and development of new drug molecule for 
the treatment of epilepsy include the MES, scPTZ, INH 
and STR models. Amongst them, the MES and scPTZ 
seizure models are the most preferred animal models for 
the screening of AEDs (Kupferberg, 2001). The MES 
test is quite sensitive to sodium (Na+) channel inhibitors 
(e.g. Phenytoin), which suggested that aryl-pyridazinone 
compounds are producing their actions by inhibiting 
voltage-gated ion channels (particularly Na+ channels). 
The INH (GABA synthesis inhibitor) and the PTZ (GABA 
antagonist) test are known to be sensitive to modulate 
γ-amino butyric acid (GABA), which suggested that 
synthesized compounds may increase the concentration 
of inhibitory neurotransmitter, GABA in the brain. The 
STR (Glycine antagonist) test is known to be sensitive to 
antagonize glycine, which suggests that compounds may 
not inhibit the glycine concentration in the brain. Thus, 
it could be proposed that the title compounds could be 
acting as voltage-gated ion channel (mainly Na+-channel) 
inhibitors and GABA modulators in the brain.
TABLE IV - Anticonvulsant activities of 6-aryl-2-(imidazol-1-yl / 
1,2,4-triazol-1-yl)-2-methyl-4,5- dihydro (2H)-pyridazin-3-one 
against pentyleneteterzole (PTZ) induced method
Compounds
Onset of 
convulsion 
(min)
No. of 
convulsion Recovery
Control 7.6±.74 1.8±0.44 00
3a 16.6±0.92 γc 1.2±0.44 80
3b 13.4±1.07 γc 1.2±0.44 80
3c 14.4±0.81 γc 1.2±0.44 60
3d 16.2±1.06 γc 1.4±0.54 80
3e 14.6±0.74 γc 1.6±0.54 80
3f 14±0.70 γc 1.2±0.44 80
3g 15±1.04 γc 1.4±0.54 60
3h 14.8±0.44 γc 1±0.00 100
3i 14.2±0.86 γc 1±0.00 100
3j 15.2±0.66 γc 1.2±0.44 100
Sodium valproate 68.2 ± 1.54 1.3±1.4 100
Phenytoin Sodium 0.00 0.00 100
Standard drug: Phenytoin sodium (25 mg.kg-1) and sodium 
valproate (100 mg.kg-1), Tested drugs: Synthesized compounds 
3a-j (50 mg.kg-1), Control group: PTZ-80 mg.kg-1+0.5% 
carboxyl methyl cellulose (CMC) in distilled water; n=5 (No. 
of animals in each group); *Value represents mean ± S.E.M. 
aP< 0.05, bP< 0.01 and cP< 0.001 when compared to control 
group; αP< 0.05, βP< 0.01 and γP< 0.001 when compared to 
standard drug sodium valproate. 
TABLE V - Anticonvulsant activities of 6-aryl-2-(imidazol-1-yl / 
1,2,4-triazol-1-yl)-2-methyl-4,5- dihydro(2H)-pyridazin-3-one 
(3a-j) against STR-induced convulsion method
Compounds
Onset of 
convulsion 
(min)
No. of 
convulsion Recovery (%)
3a 2.54±0.343 2.72±0.233 00
3b 2.60±0.383 2.80±0.153 00
3c 2.82±0.40a3 2.76±0.153 00
3d 1.92±0.293 3.0±0.163 00
3e 2.18±0.076a3 2.60±0.203 00
3f 2.88 ±1.09a2 2.74±2.183 00
3g 2.96±0.320a3 2.74±2.183 00
3h 3.12±0.39a3 2.74±2.183 00
3i 2.76±0.40a3 2.60±0.203 00
3j 2.11±0.076a3 2.80±0.153 00
Control 1.50 ±1.09 3.17±2.18 00
Sod VPA -- -- 100
PHT sod 8.45±1.86 1.06±0.78 40
Standard drug: PHT sod (25 mg.kg-1) and sod VPA (50 mg.kg-1); 
Tested drugs: Synthesized compounds 3a-j (50 mg.kg-1), Control 
group: STR 3 mg.kg-1+0.5% CMC in distilled water; n=5 (No. 
of animals/group). aP< 0.05, bP< 0.01 and cP< 0.001 when 
compared to control group. 1P< 0.05, 2P< 0.01 and 3P< 0.001 
when compared to PHT sod.
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The minimum inhibitory concentration (MIC) values 
of the screened compounds against mycobacterium were 
determined by a standard procedure. The MIC values were 
observed in the range of 1.6-6.25 μg/mL. Compounds 3a, 
3b, 3f and 3g emerged as highly potent molecules in this 
series with MIC value of 1.6 μg/mL, moderate activity 
were shown by compounds 3c, 3d, 3e and 3i with MIC 
value 3.125 μg/mL and lower activity was displayed by 
compounds 3h and 3j with MIC values 6.25 μg/mL against 
M. tuberculosis H37 Rv comparable with those of standard 
PZA (3.125 μg/mL) and STM (6.25 μg/mL) (Table VI). 
The results indicate that the pyridazine with 1,2,4-triazol-
1-yl-methyl and 4-ethylphenyl (3a), 6-biphenyl-4-yl and 
2-imidazol-1-yl-methyl (3b), 3,4-dimethyl-phenyl and 
imidazol-1-ylmethyl (3f) and 1,2,4-triazol-1-yl-methyl and 
3,4-dimethylphenyl (3g) group showed comparable activity 
with the reference drugs. 
CONCLUSIONS
A new library of aryl-pyridazinone derivatives 
were synthesized by taking a lead from the existing 
drugs. The newly synthesized 6-aryl-2-(imidazol-1-
yl / 1,2,4-triazol-1-yl)-2-methyl-4,5- dihydro (2H) 
pyridazin-3-one (3a-j) exhibited potent anticonvulsant 
and antitubercular activities in the MES, PTZ, INH 
induced seizure and MABA test, respectively. Notably 
a compound 3g showed better anticonvulsant activity 
and higher safety in MES model than marketed drugs 
sodium valproate and phenytoin sodium. All of these 
suggested that compounds 3a-j are likely to have several 
mechanisms of action including inhibition of voltage-
gated ion channels and GABAergic activity. All tested 
compounds showed moderate to good activity against 
strains of M. tuberculosis. The results demonstrate that 
both imidazol-yl-methyl and triazol-yl-methyl group 
at 2N-position of pyridazinone ring is a suitable for 
anticonvulsant as well as anti-tubercular activity.
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